Breckenridge Pharmaceutical launches Norepinephrine Bitartrate Injection, USP
23 August 2021 -

Breckenridge Pharmaceutical Inc, a subsidiary of Japan-based Towa Pharmaceutical, announced on Friday that it has introduced its Norepinephrine Bitartrate Injection, USP (generic for Levophed).

Rafarm SA, a Greek pharmaceutical company, has developed the product.

Breckenridge Pharmaceutical Inc is to market the product on its own label and provide 4mg/4mL (1mg/mL) strength in cartons of 10 vials. The United States Food and Drug Administration (FDA) earlier granted final approval of this product's Abbreviated New Drug Application (ANDA).



Related Headlines